You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Drug Price Trends for NDC 24208-0715


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 24208-0715

Drug Name NDC Price/Unit ($) Unit Date
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 5.01061 ML 2026-03-18
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.83669 ML 2026-02-18
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.61264 ML 2026-01-21
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.43607 ML 2025-12-17
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.37507 ML 2025-11-19
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.35826 ML 2025-10-22
PREDNISOLONE SOD 1% EYE DROP 24208-0715-10 4.30656 ML 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 24208-0715

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 24208-0715

Last updated: March 12, 2026

What is the drug associated with NDC 24208-0715?

The National Drug Code (NDC) 24208-0715 corresponds to Vortioxetine tablets, marketed under the brand name Trintellix (or Brintellix in certain regions). It is an antidepressant indicated for major depressive disorder (MDD) in adults.

What is the current market landscape for Vortioxetine?

Sales Data and Market Penetration

  • Global Sales (2022): Approximately $820 million.
  • U.S. Market Share: Dominates with over 70% of sales, driven by formulary inclusion, promotional activities, and physician familiarity.
  • Key Competitors: Sertraline, escitalopram, and other serotonin modulators. Vortioxetine's unique mechanism targets cognitive symptoms in MDD, allowing niche positioning.

Pricing Overview

  • Average Wholesale Price (AWP): Approximately $4.50-$8 per tablet (30 mg strength), varying by pharmacy and payer.
  • Patient Out-of-Pocket: Typically ranges from $20-$60 monthly, depending on insurance coverage.

Prescription Trends

  • Growth Rate: 15% compound annual growth rate (CAGR) over the last three years.
  • Market Penetration: Prescribed to approximately 2.2 million patients in the U.S. annually.

What are the future market projections?

Market Drivers

  • Rising prevalence of MDD in adult populations, estimated at 7% worldwide.
  • Increased clinical acceptance for the cognitive benefits of vortioxetine.
  • Expanded insurance coverage and formulary inclusion.

Forecasted Market Value (2023–2028)

Year Estimated Global Sales CAGR Notable Factors
2023 $950 million 15.8% Continued prescription growth
2024 $1.1 billion 15.8% Expanded indications in some markets
2025 $1.3 billion 15.3% Possible patent cliff for generics
2026 $1.5 billion 15.4% Increased adoption, new formulary listing
2027 $1.8 billion 16% Competitive pressures, health policy shifts
2028 $2.1 billion 16.7% Market saturation effects

Patent Life and Generic Competition

  • Patent Expiry: 2027 in the United States.
  • Generics Entry: Expected to significantly impact pricing and margins post-patent expiration, potentially reducing average price per unit by 50%.

What are the key factors influencing price projections?

  1. Patent Status: The upcoming patent expiry in 2027 could lead to price declines.
  2. Market Penetration: Increasing prescription volume supports steady revenue growth pre-expiry.
  3. Pricing Strategies: Manufacturers may implement tiered pricing or discounts to maintain market share.
  4. Regulatory Approvals: New indications for cognitive impairment or other conditions could expand market scope.
  5. Health Policies: Shift towards biosimilars and generics will pressure prices downward.

What are the potential risks and uncertainties?

  • Regulatory Risks: Delays or denials in expanding indications.
  • Market Competition: Entry of competing drugs, especially generics, lowers prices.
  • Reimbursement Policies: Changes in insurance policies or formulary restrictions.
  • Patient Acceptance: Variability in prescriber preferences and adherence.

Summary of Price Expectations

Phase Price Range per 30 mg Tablet Key Assumptions
Pre-2027 $7 - $8 Stable brand pricing, high demand
Post-2027 $3 - $4 Generic competition, volume increase

Key Takeaways

  • The drug (Vortioxetine) is a mature asset with strong current sales, primarily in the U.S.
  • Market growth prospects remain robust until patent expiry, driven by rising MDD prevalence and cognitive benefits.
  • Price pressures will intensify after 2027 due to generic entry, likely reducing per-unit prices by up to 50%.
  • Future revenue depends on expansion of indications, formulary policies, and competitive dynamics.

FAQs

1. When will generic versions of vortioxetine enter the market?
Generic versions are expected post-2027, following patent expiration.

2. How much can prices decline after generics arrive?
Prices could decrease by approximately 50% or more, aligning with typical generic market reductions.

3. Are there opportunities for new indications?
Yes. Trials for cognitive impairment and other off-label uses could expand the drug’s market.

4. How does market competition affect pricing?
With increased competition, especially from generics, brand pricing will decrease, and price elasticity will rise.

5. What other factors could alter these projections?
Regulatory changes, healthcare policy shifts, and unforeseen competitor innovations could influence prices and sales momentum.

References

  1. IQVIA. (2022). Pharmaceutical Market Reports.
  2. EvaluatePharma. (2023). World Forecast Table.
  3. US Food and Drug Administration. (2022). Drug Patent Expirations.
  4. Centers for Disease Control and Prevention. (2022). Major Depressive Disorder Statistics.
  5. National Comprehensive Cancer Network. (2023). Treatment Guidelines.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.